Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Trial of Gemcitabine Plus Docetaxel vs. Docetaxel Plus Capecitabine in Metastatic Breast Cancer in 1st and 2nd

NCT00191152 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00191152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00191152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Trial of Gemcitabine Plus Docetaxel vs. Docetaxel Plus Capecitabine in Metastatic Breast Cancer in 1st and 2nd
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2002
Completion date
November 30, 2008
Enrollment
475 (actual)
Sites
65

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast neoplasms, cancer of the breast